Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) have an increased risk of giving birth prematurely and the risk increase cannot be explained by obesity, according to… read more.
Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), the… read more.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association… read more.
Background and Aims Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs specifically designed to treat liver fibrosis…. read more.
Results from a large, retrospective Swedish study indicate that people with fatty liver disease have almost twice the risk of death in a 5-7 year period when compared… read more.
Gilead Sciences Inc. announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic… read more.
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has 16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called… read more.
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the… read more.
A common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ultimately require transplantation, according to new research… read more.
New research from Karolinska Institutet in Sweden highlights the potential benefits of screening people with type 2 diabetes for liver damage at the same time as they undergo… read more.
New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
